ArrowMark Colorado Holdings’s BridgeBio Pharma BBIO Stock Holding History

ArrowMark Colorado Holdings’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-110,011	Closed	-$8.41M	–	296
2025 Q4	$8.41M	Hold	110,011	–	–	0.19%	154
2025 Q3	$5.71M	Hold	110,011	–	–	0.11%	189
2025 Q2	$4.75M	Hold	110,011	–	–	0.09%	190
2025 Q1	$3.8M	Buy	+110,011	New	+$3.71M	0.06%	194
2024 Q4	–	Sell	-110,011	Closed	-$2.8M	–	309
2024 Q3	$2.8M	Hold	110,011	–	–	0.04%	217
2024 Q2	$2.79M	Hold	110,011	–	–	0.03%	232
2024 Q1	$116M	Hold	110,011	–	–	1.31%	20
2023 Q4	$4.44M	Hold	110,011	–	–	0.05%	212
2023 Q3	$2.61M	Buy	+110,011	New	+$3.12M	0.03%	222
2019 Q3	–	Sell	-30,000	Closed	-$809K	–	320
2019 Q2	$809K	Buy	+30,000	New	+$818K	0.01%	281

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ArrowMark Colorado Holdings's BBIO Position: Q1 2026 in Review

ArrowMark Colorado Holdings sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 110,011 shares — an estimated $8.41M sold.

ArrowMark Colorado Holdings first reported a position in BBIO in Q2 2019 and held it in 10 quarters. The position peaked at $116M in Q1 2024. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

ArrowMark Colorado Holdings reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
ArrowMark Colorado Holdings sold 110,011 BridgeBio Pharma shares in Q1 2026, an estimated $8.41M.
ArrowMark Colorado Holdings first reported a position in BridgeBio Pharma in Q2 2019 and held it in 10 quarters.
ArrowMark Colorado Holdings's BridgeBio Pharma position peaked at $116M in Q1 2024.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q1 2026, filed 15 May 2026.